PI

Forxiga is the first and only approved SGLT2i for the treatment of adults with symptomatic chronic heart failure with reduced ejection fraction1

Forxiga is the first and only approved SGLT2i for the treatment of adults with symptomatic chronic heart failure with reduced ejection fraction1

Cardiovascular, renal and metabolic diseases are some of the leading causes of death around the world.2,3 At AstraZeneca, our vision is to protect the lives of the millions of people in the UK affected by these conditions.4-6

tick-icon

New NICE recommendation

FORXIGA 10mg: Recommended as a treatment option for symptomatic chronic heart failure with reduced ejection fraction, only if added to optimised standard care (on advice of a specialist)7

 

See the DAPA-HF data that led to NICE recommendation >